ID
IDEAYA Biosciences, Inc.
IDYA · NASDAQ
$37.73 +0.05% (+$0.02)
1M +3.07%
Market Cap $3.62B
P/E Ratio -
Div. Yield -
ROE 16.47%
Bulios Fair Price
$30.08
20.3% downside
Current Price
$37.73
Undervalued Fair Value Overvalued
According to Bulios Fair Price, IDYA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
33 /100
Expensive P/B 3.02x
P/S 15.44x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 43.05%
Rev. growth 62.54%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 92.66%
Gross margin 13.32%
FCF margin 81.16%
Quality
2 /100
Poor ROA 13.36%
ROIC 17.66%
Asset turnover 0.18x
Debt
100 /100
Low Current ratio 10.45x
Debt/Equity 0.02x
Debt/Assets N/A
Stability
17 /100
Unstable EPS volatility 69.38%
Beta -0.09x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about IDYA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Yujiro S. Hata
Employees
145
Headquarters
South San Francisco
Upcoming events
09 NOV
Earnings
Upcoming earnings report